关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
  I6 ?9 B! s8 S; @% E' H7 v5 N    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。

作者：来自澳大利亚
5 ^. e7 u" f4 N8 I$ X8 s* `0 [+ G来源：Haematologica. 2011.8.9.
1 Y; B3 S* m6 l- fDear Group,

Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML
therapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
does spike up the immune system so I hope more reports come out on this issue.
" C- }7 B, o6 Q3 p: I. i* E
$ x2 M$ Q& c$ H1 o1 VThe remarkable news about Sprycel cessation is that all 3 patients had failed
9 f, b) o1 R: ^3 ]Gleevec and Sprycel was their second TKI so they had resistant disease. This is
: e: k, `7 m) y2 C2 X4 i  K6 Fdifferent from the stopping Gleevec trial in France which only targets patients
+ G* ~8 ]4 p* c4 zwho have done well on Gleevec.
, w# j) n  r' Q- t" h
Hopefully, the doctors will report on a larger study and long-term to see if the
$ d1 S5 @$ c9 R, i6 O, h" Presponse off Sprycel is sustained.
# _- c1 E* x9 z: {
( @8 w3 D  }3 j: t/ QBest Wishes,
Anjana

) v" Z5 Z- T( n1 R: T3 k

Haematologica. 2011 Aug 9. [Epub ahead of print]
, y( }9 U: A# p2 P4 rDurable complete molecular remission of chronic myeloid leukemia following
dasatinib cessation, despite adverse disease features.
Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
* S4 r- F1 A5 r2 t% m" k" K) FSource
Adelaide, Australia;
' `' W9 {/ }. I6 \+ \6 b
Abstract
Patients with chronic myeloid leukemia, treated with imatinib, who have a
* a4 F* R* g# p2 t7 k3 C, adurable complete molecular response might remain in CMR after stopping
+ M, b. p  W6 Wtreatment. Previous reports of patients stopping treatment in complete molecular
response have included only patients with a good response to imatinib. We
4 z9 `/ U, v8 r2 {describe three patients with stable complete molecular response on dasatinib
treatment following imatinib failure. Two of the three patients remain in
2 e$ Y8 ]' n+ @3 p  @complete molecular response more than 12 months after stopping dasatinib. In
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
$ f$ r) U5 R& }. z( T5 Bshow that the leukemic clone remains detectable, as we have previously shown in
imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
who relapsed and in one patient in remission. Our results suggest that the
1 |3 u# w3 f7 S& ^" d0 i- N% O# f# dcharacteristics of complete molecular response on dasatinib treatment may be
similar to that achieved with imatinib, at least in patients with adverse
1 a0 P9 z4 X  \( F( Fdisease features.
; y/ R; Z4 V' r$ K: l4 S- C

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。

& T; }& y  K- f2 r5 ?作者：来自法国STIM试验
/ Y: X+ D& b2 t5 e0 u/ h来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事